New Frontiers in Drug Discovery with AI
Simulations Plus, Inc. (NASDAQ: SLP), a leading firm in the field of biosimulation and performance solutions, is proud to announce a significant collaboration with the University of Southern California's (USC) Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences. Together, they have secured a valuable research grant from the National Institutes of Health (NIH). This endeavor aims to pioneer novel computational methodologies that focus on water-ligand interactions, a critical factor often overlooked in drug discovery, particularly in the context of virtual screening.
Enhancing Compounds with Water Interaction Insights
At the heart of this project is Dr. Ian Haworth, an associate professor at USC, along with his dedicated lab team. They will utilize the WATGEN algorithm, which has been previously developed to predict water positioning both in unbound proteins and protein-ligand complexes. Supported by a talented group of data scientists and software engineers from Simulations Plus, machine learning techniques will be integrated to forecast pharmacophore features that will enhance the capabilities of the ADMET Predictor platform.
Project Goals and Innovations
“The ability to identify chemical entities that mimic the shape and function of drug-target interactants is crucial in the pharmaceutical sector. However, the displacement or retention of water molecules during the formation of the protein-ligand interface significantly influences ligand binding. This detail has often been neglected in existing software,” noted Dr. Noam Morningstar-Kywi, a scientist at Simulations Plus and one of the key investigators for the grant. He further emphasized that the project's goal is to merge machine learning with validated calculations to incorporate these water molecules into virtual screening processes. This integration is expected to refine current methodologies and expedite the process of discovering improved therapeutic agents.
The Exciting Collaboration of Academia and Industry
Dr. Haworth expressed his enthusiasm for harnessing structure-based approaches combined with quick, accurate ligand-based similarity scoring methods. This partnership stands as a testament to the strength of collaboration between academia and industry, promising innovative solutions that could result in transformative advancements in drug development.
Real-World Applications and Testing
As part of this initiative, Simulations Plus will effectively integrate the newly developed methodologies into their ADMET Predictor platform. The team will conduct validation by designing drugs targeting specific proteins using the Artificial Intelligence-driven Drug Design (AIDD) module. Selected compounds will then undergo synthesis and experimental testing to demonstrate the practical applications of this pioneering technology in drug discovery.
Future Implications for Drug Discovery
Dr. Jeremy Jones, a principal scientist at Simulations Plus and another principal investigator on the project, shared his excitement about leveraging NIH funding to develop this groundbreaking technology for designing and testing new compounds. He anticipates that this work possesses the potential to significantly reduce the Design-Make-Test-Analyze (DMTA) cycle, drawing attention to its critical implications for advancing pharmaceutical research.
About the Collaborating Teams
The collaboration draws on Dr. Ian S. Haworth's esteemed research background. With over three decades of experience, Dr. Haworth has cultivated expertise in the dynamics of molecular interactions, specifically concerning nucleic acids and proteins. His laboratory has produced cutting-edge algorithms aiding in the understanding of these critical biomolecular processes.
About Simulations Plus, Inc.
Simulations Plus is recognized for its rich history of over 25 years in the biopharma industry, delivering robust software and consulting services that facilitate drug discovery and development. Their portfolio encompasses a multitude of innovative solutions, including advanced biosimulations that integrate AI/machine learning and population pharmacokinetic models. Serving a clientele of well-regarded pharmaceutical companies, regulatory agencies, and biotech enterprises, Simulations Plus is committed to advancing the efficiency and effectiveness of drug research and development.
Frequently Asked Questions
What is the purpose of the NIH grant awarded to Simulations Plus and USC?
The NIH grant supports research to develop new computational methods for drug discovery, focusing on water-ligand interactions.
Who is leading the research project from USC?
Dr. Ian Haworth is the Associate Professor and Vice Chair leading the project at USC.
How will the research impact drug discovery?
The research aims to incorporate essential interactions into virtual screening, potentially accelerating the identification of effective drugs.
What innovative technology is being utilized in this project?
The project will utilize machine learning and the existing ADMET Predictor platform to enhance drug design processes.
What is Simulations Plus's role in this project?
Simulations Plus will develop and validate new methodologies for drug design and discovery, integrating them into their software solutions.
